Ascendis Pharma (ASND) Commences $100M Public Offering of ADSs

October 18, 2016 4:03 PM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $100,000,000 of American Depositary Shares ("ADSs"), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") and became effective on June 2, 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Equity Offerings

Related Entities

Credit Suisse, JPMorgan, Merrill Lynch, Bank of America

Add Your Comment